

# Mudan Granules for Diabetic Peripheral Neuropathy: A Systematic Review of Preclinical and Clinical Evidence

1 **Jianlong Zhou<sup>1¶</sup>, Lv Zhu<sup>2&</sup>, Yadi Li<sup>1\*</sup>**

2 <sup>1</sup>Department of Traditional Chinese Medicine, People's Hospital of Deyang City, Deyang, China

3 <sup>2</sup>Department of Integrative Medicine, West China Hospital, Sichuan University, Chengdu, China

4

5

6 **\* Corresponding author:**

7 E-mail: [dido\\_lee0308@163.com](mailto:dido_lee0308@163.com) (Yadi Li)

8

9

10

11

12

13

14

15

16

17

18

19

20

21

## 22 **Abstract**

### 23 **Background**

24 Mudan granules has been used in China to treat diabetic peripheral neuropathy (DPN), but there is a  
25 lack of systematic review of reports in this area. The aim of this systematic review was to evaluate  
26 the efficacy and safety of Mudan granules in the treatment of diabetic peripheral neuropathy.

### 27 **Methods**

28 Initial studies were searched from PubMed, Embase, Cochrane, China National Knowledge  
29 Infrastructure (CNKI), VIP database, Wanfang electronic databases. The Cochrane Risk of Bias tool  
30 was used to evaluate the risk of bias. The meta-analysis was performed by Stata 16.0 software. For  
31 dichotomous and continuous outcomes, the relative risk (RR) and standardized mean difference  
32 (SMD) with 95% confidence interval (CI) were conducted, respectively.

### 33 **Results**

34 51 randomized controlled trials (RCTs) involving 5,416 patients were included. In the meta-analysis,  
35 compared with routine treatment (RT) alone, Mudan granules plus RT reduced Toronto clinical  
36 scoring system (TCSS) score (SMD, -0.52; 95% CI, -0.66 to -0.38;  $P < 0.01$ ), total symptoms score  
37 (TSS) (SMD, -1.44; 95% CI, -2.88 to -0.00;  $P = 0.05$ ), serum homocysteine (Hcy) levels (SMD, -  
38 3.84; 95% CI, -5.99 to -1.70;  $P < 0.01$ ), serum high sensitive C-reactive protein (hs-CRP) levels  
39 (SMD, -1.68; 95% CI, -3.29 to -0.08;  $P = 0.04$ ), and improved total clinical efficacy (RR, 1.23; 95%  
40 CI, 1.19 to 1.27;  $P < 0.01$ ) and serum superoxide dismutase (SOD) levels (SMD, 1.54; 95% CI, 1.13  
41 to 1.95;  $P < 0.01$ ). Besides, Mudan granules presented an adjuvant efficacy on median motor nerve  
42 conduction velocity (SMD, 1.61; 95% CI, 1.16 to 2.07), median sensory nerve conduction velocity  
43 (SMD, 1.73; 95% CI, 1.26 to 2.20), common peroneal motor nerve conduction velocity (SMD, 1.48;  
44 95% CI, 1.10 to 1.86), common peroneal sensory nerve conduction velocity (SMD, 1.57; 95% CI,

45 1.23 to 1.92), tibial motor nerve conduction velocity (SMD, 1.34; 95% CI, 0.82 to 1.87), and tibial  
46 sensory nerve conduction velocity (SMD, 1.03; 95% CI, 0.86 to 1.20). In terms of adverse events,  
47 there was no statistically significant difference between the trial group and the control group ( $P$   
48 =0.87). Five preclinical studies were also retrieved for the study. Animal studies have shown that  
49 Mudan granules have anti-oxidative stress effects and could reduce the inflammatory response. It  
50 may improve peripheral nerve injury in diabetic rats by modulating the TLR4/MyD88/NF- $\kappa$ B  
51 pathway, TLR4/p38 MAPK pathway and PI3K/AKT pathway.

## 52 **Conclusions**

53 Mudan granules presented an adjuvant efficacy on patients with DPN and could improve the  
54 oxidative stress and inflammatory levels in preclinical models. However, high-quality original  
55 studies are needed to further prove the evidence.

## 56 **1. Introduction**

57 Diabetic peripheral neuropathy is one of the most common chronic complications of diabetes,  
58 occurring in approximately 50% of people with diabetes(1). It is also an important cause of lower  
59 limb amputation and disabling neuropathic pain. It causes great suffering to patients in their daily  
60 lives and places a heavy economic burden on the healthcare system and society as a whole(2).  
61 Previous studies have reported prevalence rates of DPN ranging from 6% to 51%, with this variation  
62 being related to the population studied(3). 50% of people with DPN are usually asymptomatic in the  
63 early stages(4). There are also no simple markers for the early detection of DPN in routine clinical  
64 practice. DPN is defined internationally as “diabetic patients accompanied by signs and/or symptoms  
65 associated with peripheral nerve dysfunction after other causes have been excluded”(4). This  
66 definition suggests that the diagnosis of DPN is comprehensive and exclusive. A diagnosis of DPN  
67 requires 3 elements to be met. Firstly, it is necessary to have definite diabetes. Secondly, there must

68 be clinical evidence of the presence of peripheral neuropathy (signs or symptoms), and/or evidence of  
69 electrophysiological examination. Finally, other causes of peripheral neuropathy need to be ruled out  
70 by relevant laboratory tests. The Toronto Consensus recommends the use of abnormal nerve  
71 conduction studies (NCS) with signs or symptoms to diagnose DPN. The NCS is considered to be the  
72 most important basis for the diagnosis of large fiber neuropathy. Screening for DPN involves a foot  
73 examination and history taking for neurological symptoms, as well as screening tests such as the 128  
74 Hz tuning fork vibration sensing test and the 10 g (Semmes-Weinstein) monofilament test(2).  
75 However, these tests are unable to detect lesions in small nerve fibers. Skin biopsy is considered the  
76 reference for identifying small fiber neuropathy. Nevertheless, mass screening and repeat biopsies are  
77 not feasible(5). Therefore, the diagnosis of DPN, the determination of global prevalence and  
78 incidence remains a challenging task.

79 Patients with DPN usually present with symmetrical pain in the extremities, especially in the distal  
80 extremities. The most typical manifestation is abnormal sensation in the “glove-and-stockings”  
81 distribution(6). Current clinical management focuses on glycemic control, foot care and pain  
82 management(3). Strict glycemic control may stop the progression of diabetic neuropathy, but there is  
83 no evidence that glycemic control relieves pain in DPN. For the management of pain in DPN, major  
84 international clinical guidelines recommend several symptomatic treatment protocols(7). First-line  
85 treatment options include tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors and  
86 anticonvulsants that act on calcium channels. Pregabalin, gabapentin and duloxetine are the usual  
87 first-line drugs. However, tricyclic antidepressants could cause dry mouth, orthostatic hypotension,  
88 constipation, and urinary retention. Topical medications such as capsaicin and isosorbide nitrate may  
89 be considered in the second- or third-line treatment. Opioids may not be recommended as a first- or  
90 second-line treatment acute exacerbations since it is addictive(3, 8). Numerous treatments are  
91 palliative in nature and do not target the underlying mechanism causing the pain. Specifically, alpha-

92 lipoic acid and epalrestat appear to modify disease state well by modulating pathogenesis but are not  
93 recommend to by guidelines(8). Therefore, there is an urgent need to discover new therapeutic agents  
94 that can target the mechanisms.

95 Traditional Chinese medicine (TCM) has a unique theoretical system. It has accumulated rich clinical  
96 experience in the treatment of T2DM and related complications(9). The concept of DPN is not  
97 clearly described in TCM. Based on the characteristics of "numbness, pain, coldness and limb  
98 weakness", DPN belongs to the categories of "Xiaoke (emaciation and thirst)", "Xiaoke pulse Bi",  
99 "Bi syndrome" and "Wei syndrome" in the concept of TCM(6, 10). Mudan granules is a Chinese  
100 patent medicine consisting of Astragalus membranaceus (Huangqi), Corydalis rhizoma with vinegar  
101 (Yanhusuo), Panax notoginseng (Sanqi), Radix Paeoniae rubra (Chishao), Salvia miltiorrhiza  
102 (Danshen), Ligusticum chuanxiong, safflower (Honghua), Logwood (Sumu), and Caulis Spatholobi  
103 (Jixueteng)(11). It has the effects of invigorating Qi and promoting blood circulation, unblocking the  
104 meridians, and relieving pain. In China it is approved for the treatment of DPN(6). A randomised  
105 controlled trial including 148 patients with DPN showed that Mudan granules improved the  
106 conduction velocity of the common peroneal and median nerves and were effective in relieving  
107 clinical symptoms(12). Another study showed that Mudan granules combined with pancreatic  
108 kininogenase increased serum SOD level, decreased serum hypersensitive C-reactive protein (hs-  
109 CRP) level and TCSS score, and improved sensory nerve function in DPN patients(13). Therefore, in  
110 this systematic review, we evaluated clinical randomized controlled trials (RCTs) and pre-clinical  
111 studies of Mudan granules combined with RT for DPN, in order to more objectively evaluate the  
112 efficacy and safety of Mudan granules and to explore the potential mechanisms.

## 113 **2. Methods**

### 114 **2.1. Search strategy**

115 The meta-analysis followed the guidelines for Preferred Reporting Items for Systematic Reviews and  
116 Meta-analyses (PRISMA)(14) (see **S1 File** for the PRISMA checklist). The study was registered on  
117 the PROSPERO platform (CRD42022373113). The literature search was not restricted by language.  
118 The literature search was conducted using combinations of the following words: “diabetic peripheral  
119 neuropathy or diabetic or neuralgia” and “Mudan or Mu Dan”. Electronic databases, including  
120 PubMed, Embase, Cochrane, China National Knowledge Infrastructure (CNKI), VIP database,  
121 Wanfang database were searched. The detailed search strategies were provided in the additional file  
122 (see **S2 File**). In addition, we manually searched the reference lists of included clinical trials. The  
123 retrieval time range was from the establishment of the database to October 2022. Two authors  
124 (Jianlong Zhou and Lv Zhu) independently conducted the literature search based on the search  
125 strategy. Disputed sections were resolved by the third author (Yadi Li).

## 126 **2.2. Eligible criteria**

127 The inclusion criteria were as follows: (I) the study participants were clinically diagnosed with DPN;  
128 (II) the control group was treated as follows: routine treatment (e.g., diet modification, regular  
129 exercise, blood glucose control, etc.) combined or not with western medicine for the treatment of  
130 DPN; (III) Patients in the trial group were treated with Mudan granules on the basis of treatment in  
131 the control group; (IV) the study design is RCTs or preclinical studies; (V) there is no restriction on  
132 the duration of disease or treatment; (VI) outcome measures included at least one of effectiveness and  
133 safety measure; effectiveness measures included total clinical efficacy (TCE), nerve conduction  
134 velocity (NCV) including at least one of the median, common peroneal and tibial nerves, TCSS  
135 score, TSS, serum homocysteine (Hcy) level, serum hs-CRP level, serum SOD level; safety measure  
136 included adverse event rate.

137 The exclusion criteria were as follows: (I) duplicate literature; (II) review; (III) case report; (IV)  
138 clinical experience; (V) data analysis; (VI) review; (VII) non-diabetic peripheral neuropathy; (VIII)  
139 unrelated intervention; (IX) protocol or guideline; (X) non-randomised controlled trial; (XI) lack of  
140 data.

### 141 **2.3. Study screening and Data extraction**

142 We used reference management software (EndNote 20) to screen the literature. First, duplicates were  
143 identified and removed. Then, the literature was screened based on title and abstract. Finally, the full  
144 text was reviewed for eligibility based on inclusion and exclusion criteria. Two researchers (JLZ and  
145 LZ) independently assessed all retrieved literature and analysed the data according to  
146 inclusion/exclusion criteria. Disagreements were resolved by the third researcher (YDL). The  
147 relevant information was extracted and recorded using Microsoft excel software. The following  
148 information was extracted: (1) basic information of the included studies, including year of  
149 publication, name of first author, country or region, number of cases per group, baseline  
150 characteristics of subjects (age); (2) intervention and course of treatment in the trial and control  
151 groups; (3) outcome measures, including: total clinical efficacy (TCE), nerve conduction velocity  
152 (NCV) including at least one of the median, common peroneal and tibial nerves, TCSS score, TSS,  
153 serum homocysteine (Hcy) level, serum hs-CRP level, serum SOD level, adverse event. Data will be  
154 cross-checked by the third researcher to ensure quality.

### 155 **2.4. Quality assessment**

156 The study quality was also evaluated independently by two researchers (ZJL and ZL) according to  
157 the risk of bias assessment tool recommended by the Cochrane Systematic Review Manual (5.1.0).  
158 The evaluation included the following 7 items: random sequence generation; allocation concealment;

159 blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data;  
160 selective reporting; other sources of bias. Three levels of risk of bias were followed to assess: low  
161 risk, unclear risk, and high risk. Risk of bias plots for the evaluation results were drawn using the R  
162 package.

## 163 **2.5. Data analysis**

164 Stata 16.0 software (Stata Corporation, College Station, Texas, USA) was used for the meta-analysis  
165 of all data. For dichotomous data, we calculated risk ratio (RR) and 95% confidence interval (CI).  
166 Standardized mean difference (SMD) and 95% CI were calculated for continuous data. The statistical  
167 significance of differences between groups was evaluated with the Z -test, and  $P \leq 0.05$  indicated  
168 that the differences were statistically significant. The random-effect model of meta-analysis was used  
169 in the study, assuming significant heterogeneity in all the included studies. Cochran's Q test and  
170 Higgins'  $I^2$  test were used to analyze the heterogeneity between studies. When  $P > 0.05$  or  $I^2 < 50\%$ ,  
171 there is no significant heterogeneity between studies. Otherwise, it means there exists significant  
172 heterogeneity among studies. In addition, Funnel plots were used to assess the publication bias.  
173 L'Abbe plot were also used to test for heterogeneity.

## 174 **2.6. Patient and public involvement**

175 Patients and public were not involved in this study.

## 176 **3. Results**

### 177 **3.1. Literature search**



178 A total of 179 articles were retrieved according to the search strategy. After removing duplicates, 152  
179 articles potentially relevant to this study were retained. Among these, 52 articles were excluded after  
180 initial screening of titles and abstracts. After reading the full text of the remaining 100 studies, 56  
181 studies were included. All studies were conducted in China, with 51 clinical studies and 5 preclinical  
182 studies. Ultimately, 51 clinical studies were included in the meta-analysis(12, 13, 15-63). The  
183 flowchart of the retrieval is shown in **Fig 1**.

184 **Fig 1. Flow chart of literature retrieval and inclusion.**

185

## 186 **3.2. Characteristics**

187 A total of 51 studies were included in this study for quantitative analysis, involving 5416 patients,  
188 including 2752 in the trial group and 2664 in the control group. The control group was treated as  
189 follows: RT (e.g., diet modification, regular exercise, blood glucose control, etc.) combined or not  
190 with RT for DPN. Patients in the trial group were treated with Mudan granules based on treatment in  
191 the control group. The basic information of the included literature is shown in **S1 Table**.

## 192 **3.3. Methodological quality**

193 The quality of the 51 included studies was assessed using the RCT risk of bias assessment tool  
194 recommended by the Cochrane Collaboration. The results of the risk of bias assessment are shown in  
195 **Figs 2 and 3**. Three studies grouped patients according to drug regimens(37, 45, 60) and two studies  
196 grouped patients according to order of admission(49, 50), all of whom were rated as high risk. 25  
197 studies explicitly stated that patients were grouped according to rolling dice or random number table  
198 methods, all of which were rated as low risk. Studies that did not specify the method of  
199 randomization were rated as unclear risk. All randomized controlled trials without allocation

200 concealment and blinding were rated as unclear risk. All included studies showed a low risk of bias  
201 in terms of selective reporting and incomplete outcome data. Three studies were rated as high risk in  
202 term of other sources of bias because the mean age of patients enrolled was not reported(22, 25, 55).

203 **Fig 2. Risk of bias assessment of the included literature.**

204 **Fig 3. Bar chart of risk of bias assessment for the included literature.**

205

## 206 **3.4. Meta-analysis**

### 207 **3.4.1. Total clinical efficacy (TCE)**

208 A total of 41 articles reported TCE, and there was no significant heterogeneity between studies ( $I^2$   
209 =20%,  $P=0.26$ ). The results of the meta-analysis indicated that the TCE of combining Mudan  
210 granules plus RT were 1.23 times (RR 1.23, 95% CI: 1.19 to 1.27,  $P<0.01$ ) more effective than the  
211 RT for DPN, as shown in **Fig 4**. We also performed a heterogeneity test for TCE using the L'Abbe  
212 plot. The L'Abbe plot showed that all studies were above the null line and that the studies showed a  
213 more concentrated distribution. This also indicated that the efficacy of Mudan granules for DPN was  
214 superior to that of the control group, as shown in **Fig 5**.

215 **Fig 4. Forest plot of total clinical efficacy.**

216 **Fig 5. L'Abbe plot of heterogeneity test for total clinical efficacy.**

### 217 **3.4.2. Median nerve conduction velocity**

218 A total of 29 articles reported changes in median motor nerve conduction velocity before and after  
219 treatment. SMD (i.e., Cohen's d) was estimated using a random effect model. As shown in **Table 1**,  
220 the difference in median motor nerve conduction velocity before and after treatment with Mudan

221 granules based on the treatment of the control group for DPN was statistically significant (SMD 1.61,  
 222 95% CI: 1.16 to 2.07,  $P < 0.01$ ). There was a high heterogeneity between studies ( $I^2 = 96.07\%$ ,  $P$   
 223  $< 0.01$ ). A total of 27 articles reported changes in median sensory nerve conduction velocity before  
 224 and after treatment. As shown in **Table 1**, the difference in median sensory nerve conduction velocity  
 225 before and after treatment with Mudan granules was statistically significant compared with the  
 226 control group (SMD 1.73, 95% CI: 1.26 to 2.20,  $P < 0.01$ ), and there was significant heterogeneity  
 227 between studies ( $I^2 = 96.19\%$ ,  $P < 0.01$ ). The above results suggested that Mudan granules were  
 228 effective in increasing median nerve conduction velocity of patients with DPN. The detailed results  
 229 were shown in **S1 Fig**.

230 **Table 1. Meta-analysis results of other outcome measures.**

| <b>Outcome measures</b>           | <b>Pooled studies</b> | <b>Analysis mode</b> | <b><math>I^2</math></b> | <b>Effect size</b> | <b>Pooling value with 95% CI</b> | <b><math>P</math></b> |
|-----------------------------------|-----------------------|----------------------|-------------------------|--------------------|----------------------------------|-----------------------|
| <b>Median nerve MNCV</b>          | 29                    | Random effect model  | 96.07%                  | SMD                | 1.61[1.16, 2.07]                 | <0.01                 |
| <b>Median nerve SNCV</b>          | 27                    | Random effect model  | 96.19%                  | SMD                | 1.73[1.26, 2.20]                 | <0.01                 |
| <b>Common peroneal nerve MNCV</b> | 38                    | Random effect model  | 96.34%                  | SMD                | 1.48[1.10, 1.86]                 | <0.01                 |
| <b>Common peroneal nerve SNCV</b> | 35                    | Random effect model  | 95.15%                  | SMD                | 1.57[1.23, 1.92]                 | <0.01                 |
| <b>Tibial never MNCV</b>          | 8                     | Random effect model  | 92.73%                  | SMD                | 1.34[0.82, 1.87]                 | <0.01                 |
| <b>Tibial never SNCV</b>          | 5                     | Random effect model  | 0%                      | SMD                | 1.03[0.86, 1.20]                 | <0.01                 |
| <b>TCSS score</b>                 | 9                     | Random effect model  | 0%                      | SMD                | -0.52[-0.66, -0.38]              | <0.01                 |
| <b>TSS</b>                        | 5                     | Random effect model  | 97.44%                  | SMD                | -1.44[-2.88, -0.00]              | 0.05                  |

|                           |    |                     |        |     |                     |       |
|---------------------------|----|---------------------|--------|-----|---------------------|-------|
| <b>Serum Hcy level</b>    | 5  | Random effect model | 98.42% | SMD | -3.84[-5.99, -1.70] | <0.01 |
| <b>Serum hs-CRP level</b> | 11 | Random effect model | 99.39% | SMD | -1.68[-3.29, -0.08] | 0.04  |
| <b>Serum SOD level</b>    | 15 | Random effect model | 92.44% | SMD | 1.54[1.13, 1.95]    | <0.01 |
| <b>Adverse event</b>      | 20 | Random effect model | 0%     | RR  | 0.96[0.63, 1.48]    | 0.87  |

*Note.* MNCV, Motor nerve conduction velocity; SNCV, Sensory nerve conduction velocity; TCSS, Toronto clinical scoring system; TSS, Total symptom score; hs-CRP, Hypersensitive C-reactive protein; SOD, Superoxide dismutase; Hcy, Homocysteine.

231

### 232 **3.4.3. Common peroneal nerve conduction velocity**

233 A total of 38 articles reported changes in common peroneal motor nerve conduction velocity before  
 234 and after treatment. As shown in **Table 1**, the difference in common peroneal motor nerve  
 235 conduction velocity before and after treatment with Mudan granules based on the treatment of the  
 236 control group for DPN was statistically significant (SMD 1.48, 95% CI: 1.10 to 1.86,  $P < 0.01$ ).

237 There was significant heterogeneity between studies ( $I^2 = 96.34%$ ,  $P < 0.01$ ). A total of 35 articles  
 238 reported changes in common peroneal sensory nerve conduction velocity before and after treatment.  
 239 Compared with the control group, there was a statistically significant difference in the conduction  
 240 velocity of the common peroneal sensory nerve before and after treatment with Mudan granules  
 241 (SMD 1.57, 95% CI: 1.23 to 1.92,  $P < 0.01$ ), and there was significant heterogeneity between studies  
 242 ( $I^2 = 95.15%$ ,  $P < 0.01$ ). The above results suggested that Mudan granules were effective in increasing  
 243 the common peroneal nerve conduction velocity in DPN patients. The detailed results were shown in  
 244 **S2 Fig.**

#### 245 **3.4.4. Tibial nerve conduction velocity**

246 A total of 8 studies reported changes in tibial nerve motor nerve conduction velocity before and after  
247 treatment. As shown in **Table 1**, the difference in tibial nerve motor nerve conduction velocity before  
248 and after treatment with Mudan granules was statistically significant based on the treatment of DPN  
249 in the control group (SMD 1.34, 95% CI: 0.82 to 1.87,  $P < 0.01$ ). There was significant heterogeneity  
250 between studies ( $I^2 = 92.73\%$ ,  $P < 0.01$ ). A total of 5 articles reported changes in tibial nerve sensory  
251 nerve conduction velocity before and after treatment. The difference in tibial nerve sensory nerve  
252 conduction velocity before and after treatment with Mudan granules was statistically significant  
253 compared with the control group (SMD 1.03, 95% CI: 0.86 to 1.20,  $P < 0.01$ ), and there was no  
254 heterogeneity between studies ( $I^2 = 0\%$ ,  $P = 0.39$ ). These results suggested that Mudan granules could  
255 effectively improve tibial nerve conduction velocity in DPN patients. The detailed results were  
256 shown in **S3 Fig**.

#### 257 **3.4.5. Toronto Clinical Scoring System (TCSS) score**

258 A total of 9 studies reported changes in the TCSS score before and after treatment. The results of the  
259 meta-analysis showed that there was a statistically significant difference in TCSS score before and  
260 after treatment with Mudan granules compared with the control group (SMD -0.52, 95% CI: -0.66 to  
261 -0.38,  $P < 0.01$ ). There was a low heterogeneity between studies ( $I^2 = 0\%$ ,  $P = 0.76$ ), as shown in  
262 **Table 1** and **S4 Fig**. This suggested that Mudan granules may effectively reduce the TCSS score of  
263 DPN patients.

#### 264 **3.4.6. Total Symptom Score (TSS)**

265 A total of 5 articles reported changes in TSS before and after treatment. There was a high  
266 heterogeneity between studies ( $I^2 = 97.44\%$ ,  $P < 0.01$ ). The difference in TSS before and after

267 treatment with Mudan granules was statistically significant compared to the control group (SMD -  
268 1.44, 95% CI: -2.88 to -0.00,  $P=0.05$ ). This indicated that Mudan granules could effectively reduce  
269 TSS in DPN patients. As shown in **Table 1** and **S5 Fig**.

### 270 **3.4.7. Serum Hcy level**

271 A total of 5 articles reported changes in serum Hcy level before and after treatment. Compared with  
272 RT, serum Hcy level was significantly lower in Mudan granules plus RT treatment (SMD -3.84, 95%  
273 CI: -5.99 to -1.70,  $P<0.01$ ), and there was significant heterogeneity between studies ( $I^2=98.42%$ ,  $P$   
274  $<0.01$ ). As shown in **Table 1** and **S6 Fig**.

### 275 **3.4.8. Serum hs-CRP level**

276 A total of 11 studies reported the changes in serum hs-CRP level before and after treatment.  
277 Compared with RT, serum hs-CRP level was significantly lower in Mudan granules plus RT  
278 treatment (SMD -1.68, 95% CI: -3.29 to -0.08,  $P=0.04$ ), and there was significant heterogeneity  
279 between studies ( $I^2=99.39%$ ,  $P<0.01$ ). As shown in **Table 1** and **S7 Fig**.

### 280 **3.4.9. Serum SOD level**

281 A total of 15 studies reported changes in serum SOD level before and after treatment. Compared with  
282 RT alone, serum SOD level was significantly higher in Mudan granules plus RT treatment (SMD  
283 1.54, 95% CI: 1.13 to 1.95,  $P<0.01$ ), and there was a high heterogeneity between studies ( $I^2$   
284  $=92.44%$ ,  $P<0.01$ ). As shown in **Table 1** and **S8 Fig**.

### 285 **3.4.10. Adverse event**

286 A total of 20 studies reported the adverse events, with a low heterogeneity between studies ( $I^2=0%$ ,  
287  $P=0.89$ ). The difference in the rate of adverse event after Mudan granules treatment was not

288 statistically significant compared with the control group (RR 0.96, 95% CI: 0.63 to 1.48,  $P=0.87$ ), as  
289 shown in **Table 1** and **S9 Fig**. Both had low rates of adverse events, and no serious adverse events  
290 were reported.

### 291 **3.4.11. Sensitivity analysis**

292 For outcome measures without significant statistical heterogeneity, the results of the random effect  
293 model were compared with those of the fixed effect model, and the results showed that the analysis  
294 was stable and reliable.

### 295 **3.4.12. Publication bias analysis**

296 We performed a funnel plot analysis of total clinical efficacy. The funnel plot showed an uneven  
297 distribution of studies, which implies a possible publication bias, as shown in **Fig 6**. The following  
298 problems existed in the literature analysis: the large number of studies with low sample size, poor  
299 methodological design of the studies, etc. All the above factors may have caused the funnel plot to  
300 show an uneven distribution.

301 **Fig 6. Funnel plot of the total clinical efficacy of the two groups of patients.**

302

### 303 **3.4.13. Analysis of the results of preclinical studies**

304 We included 5 preclinical studies. After analyzing these articles, we summarized the possible  
305 mechanisms of Mudan granules for DPN, as shown in **Fig 7**. Animal experiments have shown that  
306 Mudan granules could improve sciatic nerve conduction velocity(64) and reduce inflammatory  
307 response by decreasing serum Hcy and TGF- $\beta$ 1 levels(65). Mudan granules are also able to increase  
308 serum glutathione (GSH) and SOD levels and reduce serum malondialdehyde (MDA) levels(66),  
309 which indicated its ability to resist oxidative stress. Several studies have also found that Mudan

310 granules could improve peripheral nerve injury by modulating the TLR4/MyD88/NF- $\kappa$ B pathway  
311 and the TLR4/p38 MAPK pathway(67). It may also alleviate neuropathic pain in diabetic rats by  
312 modulating the PI3K/AKT signaling pathway(68).

313 **Fig 7. Mechanistic plot of Mudan granules in the treatment of DPN.**

## 314 **4. Discussion**

315 In the study, we evaluated the efficacy and safety of Mudan granules in patients with DPN and  
316 explored the relevant mechanisms. Previous study included 11 RCTs and found that Mudan granules  
317 had a significant advantage over RT alone for DPN in terms of overall efficiency and improvement in  
318 the conduction velocity of the common peroneal, median, and tibial nerves. Its conclusion was that  
319 Mudan granules was effective and safe in the treatment of DPN(69). Our study also showed that  
320 Mudan granules was effective and safe in the treatment of DPN, with results consistent with previous  
321 meta-analysis. However, the main problems with these early studies were the limited sample size and  
322 the small number of outcome measures. Our study included studies from 2017 onwards and added  
323 outcome indicators such as TCSS score, TSS, Hcy, hs-CRP, and SOD. This study showed that  
324 compared with the control group, Mudan granules was able to reduce TCSS score and TSS, lower  
325 serum Hcy and hs-CRP levels, and increase SOD level.

326 Except for the low heterogeneity of outcome measures such as total clinical efficacy, TCSS score,  
327 tibial sensory nerve conduction velocity, and adverse event, the heterogeneity of Meta-analysis was  
328 greater for other measures, which may be related to the following two reasons. First, the Western  
329 medicine treatment measures were inconsistent between studies. For example, in some studies, the  
330 control group was treated with mecobalamin in addition to routine treatment, while in others it was  
331 combined with lipoic acid, and in still others, the control group was treated with epalrestat or other



332 drugs. Second, the duration of therapy varied between studies. Some studies had a treatment duration  
333 of 2 weeks, while some studies had a treatment duration of 4 weeks, and others had a treatment  
334 duration of 12 weeks.

335 There are several limitations to this meta-analysis that need to be addressed. First, despite the  
336 inclusion of RCTs, the main studies included had large biases in the methodological design, for  
337 example, all studies did not specify allocation concealment and blinding. Only 25 studies provided  
338 sufficient information about the randomization process. Second, for most of the studies, the treatment  
339 duration was not long enough to properly assess the efficacy of Mudan granule treatment. This is  
340 because DPN is a chronic disease that requires long-term treatment. The long-term efficacy and  
341 safety studies are essential to determine the therapeutic utility of the drug. However, the duration of  
342 treatment in the included studies ranged from 1 to 12 weeks, and long-term follow-up studies may  
343 yield different results. Therefore, we were unable to assess the long-term safety and efficacy of  
344 Mudan granules for the treatment of DPN. Third, study sample sizes were generally small, and most  
345 studies did not involve formal prior sample size calculations. Hence, the use of large samples in  
346 RCTs is needed to further validate the findings and avoid overestimation of intervention benefits due  
347 to insufficient sample size. Finally, although we retrieved studies published in English or Chinese  
348 databases, the language of the final included studies was Chinese, and studies published from other  
349 languages were missing. Our findings may not be well disseminated.

350 The pathogenesis of DPN is still not fully elucidated. It is commonly believed that DPN is associated  
351 with hyperglycemia, hyperlipidemia, insulin resistance and protein metabolism(5). Some studies  
352 have found that serum Hcy level was closely related to the development of DPN(70). High Hcy  
353 levels can influence the function of insulin sensitivity, oxidative stress, nitric oxide, and the pathways  
354 of vascular and neurological damage(71). Studies have shown that serum CRP levels were found to  
355 be an independent predictor of the presence of DPN(72). Elevated serum TNF- $\alpha$  and IL-10 and CRP

356 is a phenomenon associated with a pro-inflammatory response to diabetes, which was also associated  
357 with diabetic neuropathy(73). Oxidative stress caused by hyperglycemia was considered to be the  
358 initiating factor in the pathogenesis of DPN(74). Some other studies have shown that SOD is an  
359 important antioxidant enzyme. In DPN rats, serum SOD was decreased, while serum MDA was  
360 significantly increased(74). Our study found that Mudan granules were able to reduce serum Hcy, hs-  
361 CRP and MDA levels and increase serum SOD levels, which showed its anti-inflammatory and anti-  
362 oxidative stress abilities. Some studies have found that insulin deficiency or insulin resistance caused  
363 insulin receptors to promote apoptosis via the P13K/AKT pathway(6). Defective endoneurial  
364 microvasculature may lead to hypoxia and ischemia, generation of oxidative stress, and activation of  
365 the redox-sensitive transcription factor NFκB(5). Our study found that Mudan granules may improve  
366 peripheral nerve injury by modulating the TLR4/MyD88/NF-κB pathway and TLR4/p38 MAPK  
367 pathway and alleviate neuropathic pain in diabetic rats by modulating the PI3K/AKT signaling  
368 pathway. Other studies have found that the potential mechanisms of Mudan granules for DPN may  
369 include improving insulin resistance, reducing islet cell apoptosis, neuroprotection, and other  
370 effects(11, 75). Increasing evidence has suggested(76-78) that hyperlipidemia contributes to the  
371 progression of diabetic neuropathy. Total cholesterol, triglycerides, and low-density lipoprotein  
372 (LDL) cholesterol have been proved to be associated with DPN. A study on Mudan granules for  
373 diabetic dorsalis pedis atherosclerosis showed that Mudan granules could reduce serum total  
374 cholesterol, triglycerides, and LDL cholesterol levels(79). This predicted that Mudan granules may  
375 treat DPN by regulating lipid metabolism, and further studies on the lipid metabolism-related  
376 pathways of Mudan granules for DPN could follow. These studies above showed that Mudan  
377 granules may improve the development of DNP through a multi-target and multi-pathway approach.

## 378 **5. Conclusions**

379 Our systematic and meta-analytic study provides supportive evidence that Mudan granules are  
380 effective in the treatment of DPN patients based on RT, and no serious adverse events were observed.  
381 High-quality studies are essential to be conducted and further prove the preliminary evidence from  
382 the preclinical studies and clinical studies. Additionally, prolonged observation and follow-up are  
383 also needed to demonstrate the long-term efficacy and safety of Mudan granules.

## 384 **Acknowledgments**

385 None.

## 386 **Authors' Contributions**

387 Jianlong Zhou: Conceived and designed the study, drawn up the manuscript and analysed the data,  
388 prepared figures and/or tables. Lv Zhu: collected the data and performed the analysis. Yadi Li:  
389 supervised and revised the manuscript. All authors read and approved the manuscript.

390

## 391 **Reference**

- 392 1. Carmichael J, Fadavi H, Ishibashi F, Shore AC, Tavakoli M. Advances in Screening, Early  
393 Diagnosis and Accurate Staging of Diabetic Neuropathy. *Front Endocrinol.* 2021;12:25.
- 394 2. Selvarajah D, Kar D, Khunti K, Davies MJ, Scott AR, Walker J, et al. Diabetic peripheral  
395 neuropathy: advances in diagnosis and strategies for screening and early intervention. *Lancet*  
396 *Diabetes Endocrinol.* 2019;7(12):938-48.
- 397 3. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease  
398 in Diabetes. *Curr Diabetes Rep.* 2019;19(10):8.
- 399 4. Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic  
400 Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care.*  
401 2017;40(1):136-54.
- 402 5. Burgess J, Frank B, Marshall A, Khalil RS, Ponirakis G, Petropoulos IN, et al. Early  
403 Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres. *Diagnostics.*  
404 2021;11(2):39.
- 405 6. Yang K, Wang Y, Li YW, Chen YG, Xing N, Lin HB, et al. Progress in the treatment of  
406 diabetic peripheral neuropathy. *Biomed Pharmacother.* 2022;148:10.

- 407 7. Khmour MR. Treatment of diabetic peripheral neuropathy: a review. *J Pharm Pharmacol.*  
408 2020;72(7):863-72.
- 409 8. Rafiullah M, Siddiqui K. Pharmacological Treatment of Diabetic Peripheral Neuropathy: An  
410 Update. *CNS Neurol Disord-Drug Targets.* 2022;21(10):884-900.
- 411 9. Zheng WJ, Wang GF, Zhang Z, Wang ZG, Ma K. Research progress on classical traditional  
412 Chinese medicine formula Liuwei Dihuang pills in the treatment of type 2 diabetes. *Biomed*  
413 *Pharmacother.* 2020;121:7.
- 414 10. Piao YL, Liang XC. Chinese Medicine in Diabetic Peripheral Neuropathy: Experimental  
415 Research on Nerve Repair and Regeneration. *Evid-based Complement Altern Med.* 2012;2012:13.
- 416 11. Zhang YH, Jin D, Duan YY, Hao R, Chen KY, Yu TY, et al. Efficacy of Mudan Granule  
417 (Combined With Methylcobalamin) on Type 2 Diabetic Peripheral Neuropathy: Study Protocol for a  
418 Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm, Multi-Center Trial. *Front Pharmacol.*  
419 2021;12:10.
- 420 12. Xie X. Randomized parallel controlled study of treating type 2 diabetic peripheral neuropathy  
421 by Mudan particles plus western medicine. *J Pract Tradit Chin Intern Med.* 2012;26(05):53-4 (in  
422 Chinese).
- 423 13. Sun J. Mudan granule and kallidinogenase in treatment of DPN patients and the influence on  
424 SOD and hs-CRP. *Liaoning J Tradit Chin Med.* 2022;49(03):127-30 (in Chinese).
- 425 14. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The  
426 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.*  
427 2021;372:n71.
- 428 15. Zheng M, Du YB, Chen BQ, Wei GZ, Zhao Y. Clinical study of antioxidant stress of  
429 integrated traditional Chinese and western medicine on diabetic peripheral neuropathy. *Yunnan J*  
430 *Tradit Chin Med Materia Med.* 2016;37(02):30-1 (in Chinese).
- 431 16. Shen YD, Wu JF. Clinical study on kallidinogenase, Mudan granule and methylcobalamin in  
432 treatment of diabetic neuropathy. *Diabetes New World.* 2018;21(22):14-7 (in Chinese).
- 433 17. Wang YN, Yu SJ. Clinical observation of Mudan granule on the treatment of diabetic  
434 peripheral neuropathy. *J Liaoning Univ Tradit Chin Med.* 2016;18(6):87-9 (in Chinese).
- 435 18. Xia XH, Yan LH, Wang HD. Effectiveness of Mudan granules in the treatment of patients  
436 with diabetic peripheral neuropathy. *Henan Med Res.* 2020;29(24):4557-9 (in Chinese).
- 437 19. Zhang JJ, Cao W, Zhao YJ, Hu B, Wu YP. The curative effect of Mudan granule in the  
438 treatment of diabetic peripheral neuropathy and its influence on serum oxidative stress, inflammatory  
439 factors and pain substance levels. *World J Integr Tradit West Med.* 2021;16(12):2265-70 (in  
440 Chinese).
- 441 20. Mi YX, Mi YX, Zhou FJ. Clinical research on Mudan Granule in treating diabetic peripheral  
442 neuropathy. *Journal of Hunan Univ of CM.* 2013;33(11):65-7.
- 443 21. Li J, Fan FW, Tu Y. Clinical efficacy and safety of mudan granules in the treatment of  
444 diabetic peripheral neuropathy. *Chin J Clin Rati Drug Use.* 2019;12(09):70-1 (in Chinese).
- 445 22. Bai HC. Clinical observation of Mu Dan particles to treat diabetic peripheral neuropathy.  
446 *World Notes on Antibiotics.* 2013;34(03):133-4 (in Chinese).

- 447 23. Dong M, Wen ZJ, Song YQ, Chen J. The efficacy of Mudan granules in the treatment of  
448 diabetic peripheral neuropathy. *Liaoning J Tradit Chin Med*. 2015;42(07):1278-9 (in Chinese).
- 449 24. Zhang J, Qiu SL, Liang YH, Jin M. Clinical efficacy of Mudan granules in the treatment of  
450 diabetic peripheral neuropathy with Qi deficiency and blood stasis. *Beijing J Tradit Chin Med*.  
451 2016;35(12):1166-8 (in Chinese).
- 452 25. Tian H, Y., Zhang ZG. Comparison of the efficacy of mudan granules and micropowder in  
453 the treatment of diabetic peripheral neuropathy. *Mod J Integr Tradit Chin West Med*.  
454 2011;20(25):3166-7 (in Chinese).
- 455 26. Lin JH. Clinical observation of Mu Dan granule combined with mecobalamin in the treatment  
456 of diabetic peripheral neuropathy. *Chinese Community Doctors*. 2014;30(20):101-2 (in Chinese).
- 457 27. Tian W. Efficacy of the Mudan granule plus conventional western medicine on diabetic  
458 peripheral neuropathy and its electromyography. *Clin J Chin Med*. 2019;11(05):74-6 (in Chinese).
- 459 28. Zhao D. Impact of Mudan granule plus insulin on nerve conduction velocity of diabetic  
460 peripheral neuropathy patients. *Liaoning J Tradit Chin Med*. 2022;49(01):116-9 (in Chinese).
- 461 29. Wang LN, Du J, Wen ZJ, Yan Y. Efficacy of mudan granules combined with epalrestat in the  
462 treatment of diabetic peripheral neuropathy. *Liaoning J Tradit Chin Med*. 2016;43(09):1890-1 (in  
463 Chinese).
- 464 30. Liu L, Qin GJ. Efficacy of mudan granules combined with epalrestat in the treatment of  
465 diabetic peripheral neuropathy in the elderly and the effect on homocysteine. *Chin J Pract Med*.  
466 2015;42(01):85-6 (in Chinese).
- 467 31. Lai J, Wang LF, Zeng JR. A comparative study on the clinical efficacy of Mudan granules  
468 combined with western medicine in the treatment of diabetic peripheral neuropathy. *Asia-Pacific  
469 Traditional Medicine*. 2014;10(03):99-100 (in Chinese).
- 470 32. Chen D. Effect of Mudan granules combined with calcium hydroxybenzene sulfonate in the  
471 treatment of patients with diabetic peripheral neuropathy. *Medical Journal of Chinese People's  
472 Health*. 2021;33(10):85-7 (in Chinese).
- 473 33. Cui M, Peng YP, Gao JQ, Li S, Yang XS. Effects of Mudan granule combined with calcium  
474 dobesilate capsules on nerve conduction velocity, hemorheology and oxidative stress in patients with  
475 diabetic peripheral neuropathy. *Pro Mod Biomed*. 2021;21(22):4270-4 (in Chinese).
- 476 34. Zu Q, Xu BX. Effect of Mudan granules combined with alprostadil on nerve conduction  
477 velocity in patients with diabetic peripheral neuropathy. *Chin J Rati Drug Use*. 2019;16(10):12-4 (in  
478 Chinese).
- 479 35. Zhang YP, Peng XF, He F, Mao YL, Cai SY. Effect of Mudan particles combined with  
480 methylcobalamin and lipoic acid for diabetic peripheral neuropathy. *Journal of North China  
481 University of Science and Technology Health Sciences Edition*. 2016;18(06):454-7 (in Chinese).
- 482 36. Deng XJ, Ren HS. Effect of Mudan granule and thiocyanic acid injection on inflammation  
483 response and hemodynamic index in patients with diabetic peripheral neuropathy. *The Medical  
484 Forum*. 2020;24(16):2234-7 (in Chinese).
- 485 37. Yu L, Zhang W, Fu WT. Effects of Mudan granule combined with lipoic acid injection on  
486 TSS score and serum levels of SOD and Hcy in diabetic peripheral neuropathy patients. *Sichuan J  
487 Physiol Sci*. 2022;44(01):30-3 (in Chinese).

- 488 38. Gao HP. Mudan granules combined with lipoic acid and methylcobalamin for diabetic  
489 peripheral neuropathy. *Pract Clin J Integr Tradit Chin West Med*. 2018;18(02):19-21 (in Chinese).
- 490 39. Qi Y, Yu SJ. The clinical effect of Mudan particles combined with mecobalamine in the  
491 treatment of painful diabetic peripheral neuropathy. *World Chinese Medicine*. 2015;10(03):356-8 (in  
492 Chinese).
- 493 40. Qi JZ, Li L, Wang XM, Bai XP. Clinical efficacy of mudan granules combined with  
494 methylcobalamin in the treatment of diabetic peripheral neuropathy. *J Med Theor & Prac*.  
495 2019;32(11):1678-9 (in Chinese).
- 496 41. Wu WY. Effect of Mudan granule combined with mecobalamin for the treatment of diabetic  
497 peripheral neuropathy and the impact on nerve conduction velocity. *Clin Med Eng*.  
498 2018;25(08):1071-2 (in Chinese).
- 499 42. Chang C, Li Y. Clinical study of Mudan granule combined with Mecobalamin in treatment of  
500 diabetic peripheral neuropathy. *Chin J Gen Pract*. 2017;15(05):792-5 (in Chinese).
- 501 43. Xu T, Hao LM, Zhang Y, Liu CC, Liu HX. The effect of Mudan granule combined with  
502 macobalamine in the treatment of diabetic peripheral neuropathy. *World Chinese Medicine*.  
503 2017;12(02):266-8 (in Chinese).
- 504 44. Zou H, Zhang G. Clinical observation on the treatment of type 2 diabetic peripheral  
505 neuropathy with Mudan granules combined with methylcobalamin. *J Xinxiang Med Coll*.  
506 2013;30(09):759-60.
- 507 45. Qu Y, Zhang YP. Study of Mudan grabule combined with mecobalamin and a-lipoic acid in  
508 the treatment of diabetic peripheral neuropathy. *Clin Res Pract*. 2016;1(20):22-3 (in Chinese).
- 509 46. Xie YQ. Effect of Mudan granules, mecobalamine and  $\alpha$ -lipoic acid in oxidative stress for  
510 diabetic peripheral neuropathy patients. *Liaoning J Tradit Chin Med*. 2019;46(10):2109-11 (in  
511 Chinese).
- 512 47. Wu XF, Luo XH, Xu J, Xu RY, Hou HB. Effect of MuDan particles combined with cobalt  
513 amine and  $\alpha$ -lipoic acid on diabetic peripheral neuropathy. *Chin J Gen Pract*. 2015;13(12):1966-  
514 7+2029(in Chinese).
- 515 48. Yang LM, Jia RM, Gao Q, Yi JD, Li YZ. Therapeutic effect of Mudan granule combined  
516 with Mecobalamin on DPN (syndrome of deficiency of Qi)and collaterals and its influ-ence on  
517 neuroelectrophysiology and oxidative stress index. *J Clin Exp Med*. 2020;19(02):181-4 (in Chinese).
- 518 49. Zhou MQ. Efficacy of Mudan particles with methylcobalamin and gabapentin on patients  
519 with painful diabetic peripheral neuropathy. *Liaoning J Tradit Chin Med*. 2016;43(11):2317-9 (in  
520 Chinese).
- 521 50. Wang X, Cui HM, Ren F, Kong C, He Y. Effectiveness of mudan granules combined with  
522 methylcobalamin and alpha-lipoic acid in the treatment of diabetic peripheral neuropathy. *Clin Med*  
523 *Chin*. 2015;31(02):124-6 (in Chinese).
- 524 51. Chen Y. Effects of Mudan granule combined with insulin glargine on painful diabetic  
525 peripheral neuropathy. *Chin J Pract Med*. 2020;47(15):108-11 (in Chinese).
- 526 52. Wu Y. Effect of Mudan granule combined with routine western medicine on nerve  
527 conduction velocity and its curative effect on diabetic peripheral neuropathy. *Liaoning J Tradit Chin*  
528 *Med*. 2021;48(01):112-5 (in Chinese).

- 529 53. Wu HJ, Shi F, Zhang Y, Song XJ, Wang YL. Study on the effect of Mudan granule combined  
530 with beraprost sodium and epalrestat in the treatment of diabetic peripheral neuropathy. *Diabetes*  
531 *New World*. 2021;24(05):177-8+85 (in Chinese).
- 532 54. Wang LN, Du J, Dong M, Wen ZJ. Effect of Mudan granules, beraprost sodium tablets and  
533 epalrestat on diabetic peripheral neuropathy. *Liaoning J Tradit Chin Med*. 2019;46(11):2354-7 (in  
534 Chinese).
- 535 55. Feng CE, Shi ZD. Efficacy of Mudan particles combined beraprost and epalrestat for diabetic  
536 peripheral neuropathy. *Evaluation and Analysis of Drug-Use in Hospitals of China*. 2015;15(01):44-6  
537 (in Chinese).
- 538 56. Rao XJ, Wu YM. Clinical therapeutic observation of Mudan granule plus  $\alpha$ -lipoic acid in  
539 patients with diabetic peripheral neuropathy. *Chin J Pract Nerv Dis*. 2019;22(04):370-3 (in Chinese).
- 540 57. Mei LN, Wu CA. 46 cases of diabetic peripheral neuropathy treated with mudan granules  
541 combined with alpha-lipoic acid. *Zhejiang J Tradit Chin Med*. 2017;52(01):70 (in Chinese).
- 542 58. Qi Y, Yu SJ. Effect of mudan granules on oxidative stress in painful diabetic peripheral  
543 neuropathy. *Lishizhen Med Mater Med Res*. 2015;26(7):1561-3 (in Chinese).
- 544 59. Lu L, Wu L. Evaluation of the efficacy of Mudan granules in diabetic peripheral neuropathy.  
545 *Chin Remed Clin*. 2021;21(13):2294-5 (in Chinese).
- 546 60. Zhu ZQ, Cheng SJ. Effectiveness of methylcobalamin combined with Mudan granules in the  
547 treatment of diabetic peripheral neuropathy. *Mod Pract Med*. 2017;29(04):503-4 (in Chinese).
- 548 61. Wang Y, Liu L. Effectiveness of methylcobalamin combined with mudan granules in the  
549 treatment of diabetic peripheral neuropathy. *Women's Health Research*. 2019(19):123-4 (in Chinese).
- 550 62. Wen BH, Shen SM. Comparison of the curative effect of different regimens on diabetic  
551 peripheral neuropathy. *J Hunan Norm Univ (Med Sci)*. 2018;15(03):81-4 (in Chinese).
- 552 63. Xia CJ. Effect of combined treatment of diabetic peripheral neuropathy with  $\alpha$ -lipoic acid and  
553 Mudan granules on Hcy and clinical effects. *Chin Foreign Med Res*. 2016;14(09):61-3 (in Chinese).
- 554 64. Yang WQ, Yu YB, Xu XL, Ren HX, Liang JF, Zhang L. Efficacy of Mu Dan granules on  
555 experimental rats with diabetic peripheral neuropathy. *Chin J Diabetes*. 2015;23(12):1099-102 (in  
556 Chinese).
- 557 65. Sun YM, Zhao HH, Yin YL, Wang L. Effect of Mudan granule on Hcy and TGF- $\beta$ 1 in serum  
558 of rat with diabetic peripheral neuropathy in different course of disease. *Shanxi J of TCM*.  
559 2021;37(10):51-3 (in Chinese).
- 560 66. Li YY, Yu SJ. The Effect of Mudan Particles on the Oxidative Levels of Spinal Cord of  
561 Diabetic Rats. *Medical Recapitulate*. 2016;22(10):2070-3 (in Chinese).
- 562 67. Zhou M, Yao WJ. Study on Regulatory Effects of Mudan Granules on TLR4-related Pathway  
563 in DPN Rats. *Western J of TCM*. 2021;34(10):52-6 (in Chinese).
- 564 68. Qi Y, Liu YT, Zhang H, Zhao ZJ. Research of Mudan granule improved neuropathic pain in  
565 diabetic rats by regulating PI3K/AKT pathway. *Chin J Diffic and Compl Cas*. 2021;20(02):176-81  
566 (in Chinese).
- 567 69. Fang ZH, Chen XQ, Chen YM, Qiu JJ, Yang C. Meta-analysis of the efficacy of Mudan  
568 granules in the treatment of diabetic peripheral neuropathy. *Journal of New Chinese Medicine*.  
569 2017;49(08):154-8 (in Chinese).

- 570 70. Lin XY, Sun T, Yu RX, Tang YL, Li HY. Correlation between elevated serum homocysteine  
571 level and the development of diabetic peripheral neuropathy: a comparative study and meta-analysis.  
572 *Int J Clin Exp Med*. 2016;9(2):2857-64.
- 573 71. Zhao JD, Li Y, Xin L, Sun M, Yu CJ, Shi GB, et al. Clinical Features and Rules of Chinese  
574 Herbal Medicine in Diabetic Peripheral Neuropathy Patients. *Evid-based Complement Altern Med*.  
575 2020;2020:8.
- 576 72. Canpolat AG, Emral R, Keskin C, Canlar S, Sahin M, Corapcioglu D. Association of  
577 monocyte-to-high density lipoprotein-cholesterol ratio with peripheral neuropathy in patients with  
578 Type II diabetes mellitus. *Biomark Med*. 2019;13(11):907-15.
- 579 73. Nadi M, Bambaiechi E, Marandi SM. Comparison of the effect of two therapeutic exercises  
580 on the inflammatory and physiological conditions and complications of diabetic neuropathy in female  
581 patients. *Diabetes Metab Syndr Obes*. 2019;12:1493-501.
- 582 74. Zhang YZ, Zhou ZC, Song CY, Chen X. The Protective Effect and Mechanism of  
583 Dexmedetomidine on Diabetic Peripheral Neuropathy in Rats. *Front Pharmacol*. 2020;11:11.
- 584 75. Liu S-N, Sun S-J, Liu Q, Hou S-C, Shen Z-F. Effect of Mudan Granule on islets beta cell  
585 function in monosodium glutamate induced obese mice with insulin resistance: an experimental  
586 study. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi Jiehe Zazhi= Chinese Journal of*  
587 *Integrated Traditional and Western Medicine*. 2014;34(7):853-8.
- 588 76. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AAF, Feldman EL. Elevated  
589 Triglycerides Correlate With Progression of Diabetic Neuropathy. *Diabetes*. 2009;58(7):1634-40.
- 590 77. O'Brien PD, Guo K, Eid SA, Rumora AE, Hinder LM, Hayes JM, et al. Integrated lipidomic  
591 and transcriptomic analyses identify altered nerve triglycerides in mouse models of prediabetes and  
592 type 2 diabetes. *Dis Model Mech*. 2020;13(2):12.
- 593 78. Naqvi S, Imani S, Hosseinifard H, Wen QL, Shahzad MN, Ijaz I, et al. Associations of serum  
594 low-density lipoprotein and systolic blood pressure levels with type 2 diabetic patients with and  
595 without peripheral neuropathy: systemic review, meta-analysis and meta-regression analysis of  
596 observational studies. *BMC Endocr Disord*. 2019;19(1):16.
- 597 79. Guo Y, Sun Q. Effect of Mudan granule combined with zinc sulfate on ankle brachial index  
598 in diabetic foot dorsal artery sclerosis and its efficacy. *Chinese Journal of Biochemical*  
599 *Pharmaceutics*. 2016:151-4.

600

## 601 **Supporting information**

602 **S1 File. PRISMA checklist.**

603 **S2 File. The search strategies of English databases.**

604 **S1 Table. The basic information of the included literature.**



- 605 **S1 Fig. (A) Forest plot of the improvement of median motor nerve conduction velocity by**  
606 **Mudan granules. (B) Forest plot of the improvement of median sensory nerve conduction**  
607 **velocity by Mudan granules.**
- 608 **S2 Fig. (A) Forest plot of Mudan granules improving the common peroneal motor nerve**  
609 **conduction velocity. (B) Forest plot of Mudan granules improving the common peroneal**  
610 **sensory nerve conduction velocity.**
- 611 **S3 Fig. (A) Forest plot of Mudan granules improving the tibial motor nerve conduction**  
612 **velocity. (B) Forest plot of Mudan granules improving the tibial sensory nerve conduction**  
613 **velocity.**
- 614 **S4 Fig. Forest plot of Mudan granules for reducing TCSS score.**
- 615 **S5 Fig. Forest plot of TSS reduction by Mudan granules.**
- 616 **S6 Fig. Forest plot of Mudan granules reducing serum Hcy level.**
- 617 **S7 Fig. Forest plot of Mudan granule reducing serum hs-CRP level.**
- 618 **S8 Fig. Forest plot of elevated serum SOD level by Mudan granules.**
- 619 **S9 Fig. Forest plot comparing the rate of adverse events in the two groups.**

**Records identified through database searching (n=179)**  
(CNKI: 30; VIP: 131; Wan fang: 2; PubMed: 3; Embase: 8; Cochorane: 5)

medRxiv preprint doi: <https://doi.org/10.1101/2023.05.30.23290766>; this version posted June 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Records after dublicates removed (n=152)**

**Records screened (n=152)**

**Full texts assessed for eligibility (n=100)**

**Stdies included in quantitative synthesis (n=56)**

**Records excluded with reasons (n=52)**

- comments (n=8)
- case report (n=1)
- clinical experience (n=2)
- data analysis (n=3)
- review (n=13)
- not DPN (n=6)
- unrelated intervention (n=17)
- protocol or guideline (n=2)

**Full texts excluded with reasons (n=46)**

- not RCT (n=5)
- lack of data (n=39)

Risk of bias domains

|  | D1 | D2 | D3 | D4 | D5 | D6 | D7 | Overall |            |
|--|----|----|----|----|----|----|----|---------|------------|
|  | -  | -  | -  | -  | +  | +  | -  | -       | Zheng 2016 |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Shen 2018  |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Wang 2016  |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Xia 2020   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Zhang 2021 |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Mi 2013    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Li 2019    |
|  | -  | -  | -  | -  | +  | +  | ×  | ×       | Bai 2013   |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Dong 2015  |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Zhang 2016 |
|  | -  | -  | -  | -  | +  | +  | ×  | ×       | Tian 2011  |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Lin 2014   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Tian 2019  |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Sun 2022   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Zhao 2022  |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Liu 2015   |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Lai 2014   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Xie 2012   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Chen 2021  |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Cui 2021   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Zu 2019    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Deng 2020  |
|  | ×  | -  | -  | -  | +  | +  | -  | ×       | Yu 2022    |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Gao 2018   |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Qi 2015    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Qi 2019    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Wu 2018    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Chang 2017 |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Xu 2017    |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Zou 2013   |
|  | ×  | -  | -  | -  | +  | +  | -  | ×       | Qu 2016    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Xie 2019   |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Wu 2015    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Yang 2020  |
|  | ×  | -  | -  | -  | +  | +  | -  | ×       | Xie 2018   |
|  | ×  | -  | -  | -  | +  | +  | -  | ×       | Wang 2015  |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Chen 2020  |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Wu 2021    |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Wang 2019  |
|  | +  | -  | -  | -  | +  | +  | ×  | ×       | Feng 2015  |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Rao 2019   |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Mei 2017   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Lu 2021    |
|  | ×  | -  | -  | -  | +  | +  | -  | ×       | Zhu 2017   |
|  | +  | -  | -  | -  | +  | +  | -  | -       | Yan 2018   |
|  | -  | -  | -  | -  | +  | +  | -  | -       | Xiao 2016  |


medRxiv preprint doi: <https://doi.org/10.1101/2023.05.30.23290766>; this version posted June 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

Study


D1: Random sequence generation  
 D2: Allocation concealment  
 D3: Blinding of participants and personnel  
 D4: Blinding of outcome assessment  
 D5: Incomplete outcome data  
 D6: Selective reporting  
 D7: Other sources of bias

Judgement  
 Low  
 Unclear  
 High  
 Critical


Figure



Figure




Figure




Figure

# Funnel plot



Figure



Figure